Skip to content

Tirofiban versus heparin bridged with antiplatelet for the prevention of major cardiovascular and cerebrovascular events in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting

Tirofiban versus heparin bridged with antiplatelet for the prevention of major cardiovascular and cerebrovascular events in patients undergoing coronary endarterectomy combined with coronary artery bypass grafting

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055697
Enrollment
Unknown
Registered
2022-01-16
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

Sponsors

Capital Medical University Affiliated Beijing Anzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–80 years; 2. Primary diagnosis of NSTE-ACS or SIHD and appropriate candidates for isolated CABG; 3. Written informed consent before CABG surgery and ability to understand the nature of the study and the study-related procedures and to comply with them; 4. Undergoing CE-CABG.

Exclusion criteria

Exclusion criteria: 1. Severe congestive heart failure (NYHA class IV) or a left ventricular ejection fraction = 5, the operator needs to anastomosis the graft again. If PI is still >= 5 after excluding the influence of operation techniques, the operation is considered to have failed and the patient will be excluded; 13. More than 150 mL volume of the tube bleeding within 2 hours after surgery; 14. New-onset abnormal Q wave in the ECG within 2 hours after surgery; 15. Unable to complete the study or not comply with the requirements of the study (due to management or other reasons) according to the judgment of the investigators.

Design outcomes

Primary

MeasureTime frame
the cumulative tube drainage within 24 hours;The incidence of major adverse cardiovascular and cerebrovascular events in the two groups within 30 days after operation, including all-cause death, nonfatal myocardial infarction, nonfatal stroke and revascularization;

Secondary

MeasureTime frame
All cause mortality within 30 days after operation in both groups;The incidence of nonfatal myocardial infarction in the two groups within 30 days after operation;The incidence of nonfatal stroke in the two groups within 30 days after operation;The incidence of revascularization in the two groups within 30 days after operation;Postoperative renal insufficiency (serum creatinine level >= 200 µG/L, requiring acute hemodialysis, blood creatinine greater than twice the preoperative value);UDPB >= 3 within 24 hours;the incidence of TIMI major bleeding within 30 days;

Countries

China

Contacts

Public ContactYang Yu

Capital Medical University Affiliated Beijing Anzhen Hospital

13911524101@163.com+86 13911524101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026